Australia and New Zealand: An Early Phase Mecca
Publication
Dec 04, 2018
The promise of quality results, timely delivery, talented workforce and low costs have made Australia and New Zealand (ANZ) popular destinations for early phase trials. Sponsors who explore this potential with investigator buy-in ensure they enjoy a slice of the pie. This article explores how MNCs and local biopharma can best leverage the favorable regulatory environment, economic value, speed of delivery, diverse patient pool, and good infrastructure afforded by ANZ to launch their early phase studies.